Guide Debridement with the MolecuLight i:X™

A patient with a diabetic foot ulcer used over-the-counter antibiotic ointment for over two months before seeking treatment from a wound care practitioner. The patient’s lack of awareness of his condition, improper footwear, and delay of treatment were likely factors that led to infection. Treatment for the wound required frequent debridement, as there was rapid callus build-up. Antimicrobial foam, offloading, and local wound care were also part of the patient’s general care paradigm.

Pre-debridement, the clinician observed no red fluorescing bacteria (Figure 2). However, after debridement, the images revealed red fluorescence (Figure 4), indicating that there were indeed bacteria present in the wound. The clinician then continued to debride using MolecuLight i:X guidance until the red fluorescing bacteria were no longer detected (Figure 6).

Using the MolecuLight i:X throughout treatment not only helped the clinician target debridement to areas of red fluorescing bacteria, but also emphasized the importance of regular debridement in a clinical setting. The patient was shown images of his wound throughout the MolecuLight i:X guided debridement process, which helped him better understand bacterial infection and the severity of his condition. Visual documentation of the wound’s progress also helped the clinician and patient observe the effectiveness of the treatment over time.

The MolecuLight i:X™ Imaging Device is not available in the US.
Testimonial

“Guiding debridement with the MolecuLight i:X reassured me that I was targeting regions of bioburden and avoiding unburdened tissue – which provided a more optimal state for wound healing.”

— Rose Raizman RN-EC, MSc

Visit moleculight.com
+1.647.362.4684
Toll Free 1.877.818.4360 (Canada)
info@moleculight.com

Follow us: 

References:
Images provided by Rose Raizman, RN-EC, MSc, Scarborough & Rouge Hospital, ON, Canada MolecuLight Clinical Case 0045.

©2018 MolecuLight Inc. All Rights Reserved. PN 1367 Rev 1.0

The MolecuLight i:X™ Imaging Device is approved by Health Canada (Medical License #895784) and has CE marking (Certificate #511 16029395500) for sale in Canada and the European Union. The MolecuLight i:X™ Imaging Device is not available in the US.

MolecuLight® and Look to Heal® are Registered Trademarks in Canada, the US, and the EU.

MolecuLight i:X™ Wound Intelligence Device

The MolecuLight i:X allows clinicians to quickly, safely and easily visualize bacteria¹ and measure wounds² at the point of care so they have maximum insights for accurate treatment selection and accelerated healing.¹

Bacteria appear red in image